Published ahead of print on March 18, 2005, doi:10.1164/rccm.200408-1001OC
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 1421-1429, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200408-1001OC
Dual Role of Vascular Endothelial Growth Factor in Experimental Obliterative Bronchiolitis
Rainer Krebs,
Jussi M. Tikkanen,
Antti I. Nykänen,
Jeanette Wood,
Michael Jeltsch,
Seppo Ylä-Herttuala,
Petri K. Koskinen and
Karl B. Lemström
Cardiopulmonary Research Group, Transplantation Laboratory, University of Helsinki/Helsinki University Central Hospital; Molecular Cancer Biology Laboratory, Biomedicum Helsinki, University of Helsinki; Division of Nephrology, Department of Medicine, and Department of Cardiothoracic Surgery, Helsinki University Central Hospital, Helsinki; A.I. Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland; and Novartis Pharma, Basel, Switzerland
Correspondence and requests for reprints should be addressed to Karl Lemström, M.D., Ph.D., Transplantation Laboratory, P.O. Box 21 (Haartmaninkatu 3), FIN-00014 Helsinki, Finland. E-mail: karl.lemstrom{at}helsinki.fi
Obliterative bronchiolitis (OB) is the major limitation for long-term survival of lung allograft recipients. We investigated the role of vascular endothelial growth factor (VEGF) in the development of OB in rat tracheal allografts. In nonimmunosuppressed allografts, VEGF mRNA and protein expression vanished in the epithelium and increased in smooth muscle cells and mononuclear inflammatory cells with progressive loss of epithelium and airway occlusion compared with syngeneic grafts. Intragraft VEGF overexpression by adenoviral transfer of a mouse VEGF164 gene increased early epithelial cell proliferation and regeneration but increased microvascular remodeling and lymphangiogenesis and luminal occlusion by more than 50% compared with AdlacZ-treated allografts. Although VEGF receptor inhibition decreased early epithelial regeneration in noninfected allografts, it reduced microvascular remodeling, lymphangiogenesis, intragraft traffic of CD4+ and CD8+ T cells, and the degree of luminal occlusion. Simultaneous VEGF gene transfer and platelet-derived growth factor receptor inhibition with imatinib preserved respiratory epithelium and totally prevented luminal occlusion. In conclusion, our findings indicate that VEGF has a dual role in transplant OB. Our results suggest that VEGF may protect epithelial integrity. On the other hand, VEGF may enhance luminal occlusion by increasing the recruitment of mononuclear inflammatory cells with platelet-derived growth factor acting as a final effector molecule in this process.
Key Words: angiogenic growth factors lung transplantation
This article has been cited by other articles:

|
 |

|
 |
 
M. G. Saueressig, A. M. Neto, E. A.F. Fortis, D. Westphal, M. I.A. Edelweiss, L. Meurer, and U. Matte
Vascular endothelial growth factor gene therapy induces early re-establishment of canine bronchial circulation
Eur. J. Cardiothorac. Surg.,
April 1, 2008;
33(4):
717 - 722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. A. Goers, S. Ramachandran, A. Aloush, E. Trulock, G. A. Patterson, and T. Mohanakumar
De Novo Production of K-{alpha}1 Tubulin-Specific Antibodies: Role in Chronic Lung Allograft Rejection
J. Immunol.,
April 1, 2008;
180(7):
4487 - 4494.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Murphy, I. A. Forrest, P. A. Corris, G. E. Johnson, T. Small, D. Jones, A. J. Fisher, J. J. Egan, T. E. Cawston, C. Ward, et al.
Simvastatin attenuates release of neutrophilic and remodeling factors from primary bronchial epithelial cells derived from stable lung transplant recipients
Am J Physiol Lung Cell Mol Physiol,
March 1, 2008;
294(3):
L592 - L599.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Okazaki, A. E. Gelman, J. R. Tietjens, A. Ibricevic, C. G. Kornfeld, H. J. Huang, S. B. Richardson, J. Lai, J. R. Garbow, G. A. Patterson, et al.
Maintenance of Airway Epithelium in Acutely Rejected Orthotopic Vascularized Mouse Lung Transplants
Am. J. Respir. Cell Mol. Biol.,
December 1, 2007;
37(6):
625 - 630.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Panoskaltsis-Mortari, K. V. Tram, A. P. Price, C. H. Wendt, and B. R. Blazar
A New Murine Model for Bronchiolitis Obliterans Post Bone Marrow Transplant
Am. J. Respir. Crit. Care Med.,
October 1, 2007;
176(7):
713 - 723.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Tikkanen, M. Hollmen, A. I. Nykanen, J. Wood, P. K. Koskinen, and K. B. Lemstrom
Role of Platelet-derived Growth Factor and Vascular Endothelial Growth Factor in Obliterative Airway Disease
Am. J. Respir. Crit. Care Med.,
November 15, 2006;
174(10):
1145 - 1152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Luckraz, M. Goddard, K. McNeil, C. Atkinson, L. D. Sharples, and J. Wallwork
Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways?
Ann. Thorac. Surg.,
October 1, 2006;
82(4):
1212 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Estenne and R. M. Kotloff
Update in transplantation 2005.
Am. J. Respir. Crit. Care Med.,
March 15, 2006;
173(6):
593 - 598.
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|